Patent: 9,526,764
✉ Email this page to a colleague
Summary for Patent: 9,526,764
Title: | Combination of an insulin and a GLP-1-agonist |
Abstract: | The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist. |
Inventor(s): | Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE) |
Assignee: | SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE) |
Application Number: | 13/123,835 |
Patent Claims: | see list of patent claims |
Details for Patent 9,526,764
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2028-10-17 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/25/2007 | ⤷ Try a Trial | 2028-10-17 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 12/16/2015 | ⤷ Try a Trial | 2028-10-17 |
Eli Lilly And Company | BASAGLAR | insulin glargine | Injection | 205692 | 11/15/2019 | ⤷ Try a Trial | 2028-10-17 |
Mylan Pharmaceuticals Inc. | SEMGLEE | insulin glargine | Injection | 210605 | 06/11/2020 | ⤷ Try a Trial | 2028-10-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |